Vivani Medical (VANI) said Thursday that it has completed enrolling participants in its initial clinical trial testing NPM-115, a subdermal GLP-1 implant for overweight adults with type 2 diabetes.

The company said the first patient received the implant as part of the study, which is designed to evaluate drug absorption and safety over a six-month period.

Vivani said the enrollment concluded about four weeks after the first subject was dosed, with preliminary results expected by mid-2025.

The company's shares were up more than 2% in recent Thursday premarket activity.